Large gap with delayed quotes
|
Last quote
03/24/2026
-
17:31:17
|
Bid
03/24/2026 -
17:31:17
|
Bid Volume |
Ask
03/24/2026 -
17:40:00
|
Ask Volume |
|---|---|---|---|---|
|
3.365
+0.015
(
+0.45% )
|
3.31
|
2,212 |
3.65
|
6,253 |
Analysis date: 20.03.2026
Global Evaluation
Neutral
Neutral
The stock is classified in the neutral zone since 20.03.2026.
Interest
Weak
Weak
Two stars since 20.03.2026.
Earnings Rev Trend
Positive
Positive
Compared to seven weeks ago, the analysts have raised their earnings per share estimates. This positive trend began 20.02.2026 at a price of 3.70.
Evaluation
Strongly overvalued
Strongly overvalued
Based on its growth potential and our own criteria, we believe the share price is currently overvalued.
MT Tech Trend
Neutral
Neutral
The stock is currently trading close to its dividend-adjusted forty day moving average (changes between +1.75% and -1.75% are considered neutral). Prior to this, the stock traded below its moving average since 13.03.2026.
4wk Rel Perf
6.65%
6.65%
The four-week dividend-adjusted overperformance versus STOXX600 is 6.65%.
Sensibility
Middle
Middle
The stock has been on the moderate-sensitivity level since 17.03.2026.
Bear Market Factor
Low
Low
On average, the stock has a tendency to minimize the drops in the index by -1.63%.
Bad News Factor
Low
Low
When the stock's pressure is specific, the market sanction on average is 3.35%.
Mkt Cap in $bn
0.19
0.19
With a market capitalization <$2bn, MOLECULAR PARTNERS is considered a small-cap stock.
G/PE Ratio
2.66
2.66
A ratio (Forecasted Growth + Estimated Dividend Yield/ Estimated Price Earnings) higher than 1.6 often suggests the projected growth is a result of a base effect, meaning the company can often be in a turn around situation. In this case, the estimated PE is a better indicator of a stock's expected growth than the Long Term Growth (LT Growth).
LT P/E
-2.27
-2.27
The estimated PE is negative: the financial analysts' earnings estimates forecast a loss.
LT Growth
3.00%
3.00%
The annualized growth estimate is for the current year to 2027.
Avg. Nb analysts
6
6
Over the last seven weeks, an average of 6 analysts provided earnings per share estimates.
Dividend Yield
3.04%
3.04%
The earnings forecasts are not sufficient to cover the twelve month estimated dividend.
Beta
2
2
For 1% of index variation, the stock varies on average by 0.02%.
Correlation
0.01
0.01
Stock movements are totally independent of index variations.
Value at Risk
0.81
0.81
The value at risk is estimated at CHF 0.81. The risk is therefore 22.52%. This value is based on the historical volatility for a medium time period (1 month) with a confidence of 95%.
First Analysis Date
12.08.2016
12.08.2016